Badrinath R. Konety MD, MBA, FACSProfessor and Dougherty Family Chair in Urologic Oncology, Department of Urology; Director, Institute for Prostate and Urologic Cancer; Associate Dean for Innovation, University of Minnesota, Minneapolis, Minnesota
Badrinath R. Konety, MD, MBA, is a Professor in the Department of Urology and holds the Dougherty Family Chair in Uro-Oncology as well as being the Director of the Institute for Prostate and Urologic Cancers at the University of Minnesota. He is the former chair of the Department of Urology, Associate Director for Clinical Affairs of the Masonic Cancer Center at the University of Minnesota and Associate Dean for Strategy and Innovation of the Medical School.
Badrinath Konety, M.D., completed his residency and American Foundation for Urologic Disease Research Scholar fellowship at the University of Pittsburgh. He also received an MBA from the University of Pittsburgh Katz School of Business. Dr. Konety also completed his urologic oncology fellowship at Memorial Sloan Kettering Cancer Center.
He has authored or co-authored 250 original publications and numerous book chapters as well as editing a text on bladder cancer. He has been and is principal or co-investigator on grants funded through the Department of Defense, National Institutes of Health, American Geriatrics Society and Center for Disease Control. He received the Jahnigen Career Development Scholar Award, and is an active member of numerous professional medical societies including the American Urological Association, the American College of Surgeons, Societe Internationale D’Urologie and the American Association of Genitourinary Surgeons. He is currently the Past President of the SIU, the Society of Academic Urology and Associate Editor of the Journal of Urology.
DisclosuresDr. Konety has nothing to disclose.
Recent Contributions to PracticeUpdate:
- Utilization and Outcomes of Metastasectomy for Patients With Metastatic Urothelial Cancer
- Perioperative Antimicrobial Prophylaxis for Preventing Infectious Complications After TURBT
- Patient-Reported Quality-of-Life Outcomes of Muscle-Invasive Bladder Cancer Treated With Radiotherapy ± Chemotherapy
- Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging Reporting and Data System for Muscle-Invasive Bladder Cancer
- Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants
- A Cost-Effectiveness Modeling Study of Robot-Assisted vs Open Radical Cystectomy for Bladder Cancer
- Use of the American Urological Association Clinical Practice Guidelines
- Impact of Blood Transfusion During Radical Cystectomy and Urinary Diversion on Cancer-Related Outcome and Survival
- CKD as a Risk Factor in Patients With Non–Muscle Invasive Bladder Cancer
- Evaluation of the Timing of Surgical Complications Following Radical Cystectomy